Director/PDMR Shareholding

RNS Number : 0927V

Genedrive PLC

19 July 2018

 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that it on 17 July 2018 share options ("Options") were granted to certain of its directors to acquire a total of 486,306 ordinary shares of 1.5p each in the capital of the Company under the Company's 2017 Share Option Scheme.

The Options have been granted with an exercise price equal to the closing price on the day before grant and vest after a period of three years if certain performance criteria are met.  The Options are exercisable over the period of 10 years from the date of grant.

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	1.   David Budd 2.   Matthew Fowler
2.	Reason for the notification
a.	Position/status	1.   CEO 2.   CFO
a.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	genedrive plc
b.	LEI	213800ZYODIRZ87Y4K14
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Options over ordinary shares of 1.5 pence each
b.	Nature of the transaction	Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 5 December 2017.
c.	Price(s) and volume(s)	Price(s) Option price(s) Volume(s) David Budd 30.5p 222,260 Matthew Fowler 30.5p 264,046
d.	Aggregated information ·      Aggregated volume ·      Price	N/A
e.	Date of the transaction	2018-17-07; UTC time
f.	Place of the transaction	Outside trading venue - shares to be admitted to AIM market of London Stock Exchange plc on exercise of options

For further details please contact:

genedrive plc	[phone]
David Budd: CEO
Matthew Fowler: CFO
Peel Hunt LLP	[phone]
James Steel
Oliver Jackson
Stanhope Capital Ltd	[phone]
Patrick Claridge
Consilium Strategic Communications	[phone]
Chris Gardner
Matthew Neal
Laura Thornton
[e-mail]

 

END

 

 

DSHEANXPFFDPEFF